Across TCGA pan-cancer cohorts, ZBTB3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZBTB3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZBTB3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBTB3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and HNSC are the cancer types where ZBTB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.926	0.414	.010	10	view →
GBM	OS	Median	All	0.585	0.288	.045	2	view →
HNSC	DFS	Median	All	1.000	0.855	.040	1	view →
LSCC	OS	Median	II,III,IV	0.910	0.802	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZBTB3 tumor-vs-normal RNA expression · all ZBTB3 data types